NIH Center Would Seek To Boost “Repurposing” Of Shelved Drug Candidates
Executive Summary
A proposed new center at the National Institutes of Health dedicated to speeding “translation” of biomedical research into therapies may focus initially on exploring new uses for drug candidates shelved by pharmaceutical firms, according to NIH Director Francis Collins.
You may also be interested in...
NIH Repurposing Of Failed Compounds Could Begin Soon; NCATS Plans Pilots
The National Center for Advancing Translational Science soon may have an agreement with one or more firms to allow research to test abandoned compounds for new uses, NIH Deputy Director for Science, Outreach and Policy Kathy Hudson says. NIH has sought, and will continue to seek, industry input on where NCATS should put its efforts to speed translation of drugs from the bench to the market, she notes.
NIH Translational Center To Study Cell-Based Toxicity Tests, Offer Industry Grants
Toxicity testing is one area in which NIH Director Francis Collins expects the proposed National Center for Advancing Translational Science to help industry speed up drug development.
NIH Translational Center To Study Cell-Based Toxicity Tests, Offer Industry Grants
Toxicity testing is one area in which NIH Director Francis Collins expects the proposed National Center for Advancing Translational Science to help industry speed up drug development.